SkinBioTherapeutics plc (AIM:SBTX)
9.70
+0.20 (2.11%)
Sep 4, 2026, 3:21 PM GMT
SkinBioTherapeutics Cash Flow Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | -0.46 | -0.7 | -2.88 | -2.84 | -2.79 | -1.43 |
Depreciation & Amortization | 0.54 | 0.43 | 0.18 | 0.05 | 0.04 | 0.01 |
Loss (Gain) From Sale of Assets | 0.03 | 0.03 | - | - | - | - |
Stock-Based Compensation | - | - | - | 0 | 0.05 | 0.06 |
Other Operating Activities | -0.65 | -0.43 | 0.15 | 0.08 | -0.08 | -0.07 |
Change in Accounts Receivable | -0.92 | -0.75 | 0.17 | -0.05 | 0.13 | -0.2 |
Change in Inventory | -0.1 | 0.01 | 0.1 | 0.09 | -0.12 | - |
Change in Accounts Payable | -0.38 | 0.17 | -0.44 | 0.02 | 0.1 | 0.07 |
Operating Cash Flow | -1.94 | -1.24 | -2.73 | -2.65 | -2.67 | -1.56 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Capital Expenditures | -0.03 | -0.01 | -0.01 | -0.09 | - | - |
Sale (Purchase) of Intangibles | -0.11 | -0.15 | -0.17 | -0.08 | -0.1 | -0.11 |
Other Investing Activities | -0.04 | -1.46 | -2.11 | 0 | - | -0 |
Investing Cash Flow | -0.18 | -1.62 | -2.3 | -0.17 | -0.1 | -0.11 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Short-Term Debt Issued | - | - | 1.47 | - | - | - |
Long-Term Debt Issued | - | 0.95 | - | - | - | - |
Total Debt Issued | - | 0.95 | 1.47 | - | - | - |
Long-Term Debt Repaid | - | -0.11 | -0.04 | -0.04 | -0.04 | -0 |
Lease Payments | -0.15 | -0.11 | -0.04 | -0.04 | -0.04 | -0 |
Net Debt Issued (Repaid) | -0.15 | 0.84 | 1.43 | -0.04 | -0.04 | -0 |
Issuance of Common Stock | 4.24 | 6.06 | 3.12 | 2.62 | - | 4.12 |
Other Financing Activities | -0.08 | -0.06 | -0.04 | -0.26 | - | - |
Financing Cash Flow | 4.01 | 6.83 | 4.51 | 2.32 | -0.04 | 4.12 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash Flow | 1.89 | 3.98 | -0.51 | -0.49 | -2.8 | 2.45 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Free Cash Flow | -1.97 | -1.24 | -2.74 | -2.73 | -2.67 | -1.56 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -37.68% | -26.76% | -226.80% | -2071.02% | -3575.44% | - |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 |
Levered Free Cash Flow | -1.41 | -1.62 | -1.79 | -1.86 | -1.85 | -1.17 |
Unlevered Free Cash Flow | -1.33 | -1.56 | -1.76 | -1.85 | -1.84 | -1.17 |
Free Cash Flow After Leases | -2.12 | -1.35 | -2.78 | -2.77 | -2.71 | -1.56 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash Interest Paid | 0.08 | 0.06 | 0.04 | - | - | - |
Cash Income Tax Paid | - | -0.03 | -0.18 | -0.26 | -0.12 | - |
Change in Working Capital | -1.4 | -0.57 | -0.17 | 0.05 | 0.11 | -0.12 |